Adverum Biotechnologies Competitors and Similar CompaniesClear all

Adverum Biotechnologies's competitors and similar companies include SwanBio Therapeutics, Generation Bio, Kelonia Therapeutics and Ultragenyx.

	Adverum Biotechnologies Adverum Biotechnologies (formerly known as Avalanche Biotechnologies) is a clinical-stage gene therapy company targeting unmet medical need in ophthalmology and rare diseases.	SwanBio Therapeutics SwanBio Therapeutics is a gene therapy company developing medicines for the treatment of neurological diseases.	Generation Bio Generation Bio is a genetic medicines company creating gene therapy.	Kelonia Therapeutics Kelonia Therapeutics is a biotech company developing genetic medicines using a gene delivery platform.	Ultragenyx Ultragenyx Pharmaceutical is a company that develops therapies for rare genetic diseases.
Founding Date	Founding Date 2006	Founding Date 2018	Founding Date 2016	Founding Date 2020	Founding Date 2010
Type	Type Public	Type Private	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development genetics therapy	Tags Healthcare biotech drug development genetics therapy	Tags Healthcare biotech drug development genetics therapy	Tags Healthcare biotech drug development genetics oncology therapy	Tags Healthcare biotech drug development genetics pharma therapy
Locations	Locations Redwood City, US HQ Philadelphia, US	Locations Philadelphia, US HQ Cambridge, US	Locations Cambridge, US HQ	Locations Boston, US HQ	Locations Novato, US HQ Buenos Aires, AR São Paulo, BR Bogotá, CO Paris, FR Berlin, DE Tokyo, JP see more
Employees	Employees 11419% increase	Employees 625% decrease	Employees 85	Employees 643% increase	Employees 1,2763% decrease
Valuation ($)	Valuation ($) 161.4 m	Valuation ($) N/A	Valuation ($) 159.5 m	Valuation ($) N/A	Valuation ($) 4.9 b
Financial
Revenue (est.)	Revenue (est.) $1m (FY, 2024)	Revenue (est.) N/A	Revenue (est.) $19.9m (FY, 2024)	Revenue (est.) N/A	Revenue (est.) $673m (FY, 2025)
Net income	Net income ($130.9m) (FY, 2024)	Net income N/A	Net income ($131.7m) (FY, 2024)	Net income N/A	Net income ($575m) (FY, 2025)
Funding
Latest funding round	Latest funding round N/A	Latest funding round $ 52m (about 6 years ago)	Latest funding round N/A	Latest funding round $ 50m (about 4 years ago)	Latest funding round N/A
Total funding raised	Total funding raised $ 70.7m	Total funding raised $ 52m	Total funding raised $ 235m	Total funding raised $ 50m	Total funding raised $ 200.1m